These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 8574612

  • 1. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
    Constantin A, Laroche M, Moulinier L, Bon E, Ramonjisoa M, Cantagrel A, Mazieres B.
    Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
    [Abstract] [Full Text] [Related]

  • 2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects of intravenous alendronate in Paget's disease of bone.
    O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA.
    J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
    [Abstract] [Full Text] [Related]

  • 7. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
    Vega E, Gonzalez D, Ghiringhelli G, Mautalen C.
    J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
    [Abstract] [Full Text] [Related]

  • 8. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
    Stone MD, Hawthorne AB, Kerr D, Webster G, Hosking DJ.
    J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
    [Abstract] [Full Text] [Related]

  • 9. [Renal tubular function in children with hypercalciuria].
    Kovacević L, Kovacević S, Smoljanić Z, Kostić M, Peco-Antić A, Gajić M, Kovacević M, Jovanović O.
    Srp Arh Celok Lek; 1998 Dec; 126(7-8):223-7. PubMed ID: 9863386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
    Price RI, Gutteridge DH, Stuckey BG, Kent GN, Retallack RW, Prince RL, Bhagat CI, Johnston CA, Nicholson GC, Stewart GO.
    J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
    [Abstract] [Full Text] [Related]

  • 12. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V.
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease.
    Naylor KE, Jackson B, Eastell R.
    J Bone Miner Res; 2003 Apr; 18(4):658-61. PubMed ID: 12674326
    [Abstract] [Full Text] [Related]

  • 15. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH.
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [Abstract] [Full Text] [Related]

  • 17. Paget's disease of bone: experience from a centre in southern India.
    Anjali, Thomas N, Rajaratnam S, Shanthly N, Oommen R, Seshadri MS.
    J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899
    [Abstract] [Full Text] [Related]

  • 18. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation.
    Mangham DC, Davie MW, Grimer RJ.
    Bone; 2009 Mar; 44(3):431-6. PubMed ID: 19064007
    [Abstract] [Full Text] [Related]

  • 19. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ, Gunasekera RD.
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [Abstract] [Full Text] [Related]

  • 20. The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study.
    Bender T, Donáth J, Barna I, Gergely P, Poór G.
    Neuro Endocrinol Lett; 2006 Aug; 27(4):513-5. PubMed ID: 16891991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.